19185-89-8

Upstream product

• 2232-58-8 (Z)-6-Methoxy-hex-5-en-3-yn-2-ol 
• 82456-95-9 (1R,2S,6R)-2-Methoxy-4-methyl-3,7-dioxa-bicyclo[4.1.0]heptane 
• 54125-02-9 danishefsky's diene 
• 75-07-0 acetaldehyde 
• 80754-64-9 (6-Methoxy-2-methyl-3,6-dihydro-2H-pyran-4-yloxy)-trimethyl-silane 

Downstream Products

• 14505-80-7 (+/-)-trans-2,6-dimethyltetrahydropyran-4-one 
• 34819-86-8 Acetic acid (2S,4S)-4-acetoxy-2-methyl-3,4-dihydro-2H-pyran-3-yl ester 
• 1193-20-0 2-methyltetrahydro-4H-pyran-4-one 
• 14505-80-7 (2S,6S)-2,6-dimethyl-3,4,5,6-tetrahydro-2H-pyran-4-one 
• 1393537-57-9 dimethyl (4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl((2S)-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate 
• 1393537-53-5 dimethyl ((3-fluoro-4,4'-biphenyldiyl)bis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate 
• 1393537-51-3 dimethyl ((3-methyl-4,4'-biphenyldiyl)bis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate 
• 1393645-23-2 dimethyl (4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate 
• 1359976-82-1 (S)-benzyl 2-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-(methoxycarbonylamino)acetate 
• 1359976-81-0 (S)-benzyl 2-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-(diphenylmethyleneamino)acetate 
• 1359976-80-9 (R)-benzyl 2-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-(diphenylmethyleneamino)acetate 
• 1053231-38-1 (2R,6R)-2,6-dimethyldihydro-2H-pyran-4(3H)-one 

Relevant academic research and scientific papers

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of formula I, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in th

NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS

The present invention relates to novel 4- (heterocycloalkyl) benzene- 1,3-diol compounds corresponding to general formula (I) below: to the compositions containing same, to the process for the preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions for use in the treatment or prevention of pigmentary disorders

INHIBITORS OF SERINE PROTEASES

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

Callipeltoside A: Total synthesis, assignment of the absolute and relative configuration, and evaluation of synthetic analogues

The total synthesis of the novel antitumor agent callipeltoside A, as well as several analogues, is accomplished and allows assignment of the stereochemistry not previously established. A convergent strategy is employed wherein the target is dissected into three units - the core macrolactone, the sugar callipeltose, and a cyclopropyl bearing chain. The strategy for the synthesis of the macrolactone derives from employment of diastereoselective aldol reactions that emanate from an 11 carbon piece. The stereochemistry of the latter derives from the chiral pool and two asymmetric reactions - a ketone reduction using CBS-oxazaborolidine and a Pd catalyzed asymmetric allylic alkylation (AAA). The novelty of the latter protocol is its control of regioselectivity as well as absolute configuration. The trisubstituted olefin is generated using an alkene-alkyne coupling to create a trisubustituted olefin with complete control of geometry. The excellent chemo- and regioselectivity highlights the synthetic potential of this new ruthenium catalyzed process. The macrolactonization employs in situ formation of an acylketene generated by the thermolysis of a m-dioxolenone. Two strategies evolved for attachment of the side chain-one based upon olefination and a second upon olefin metathesis. The higher efficiency of the latter makes it the method of choice. A novel one pot olefin metathesis-Takai olefination protocol that should be broadly applicable is developed. The sugar is attached by a glycosylation by employing the O-trichloroacetimidate. This route provided both C-13 epimers of the macrolactone by using either enantiomeric ligand in the Pd AAA reaction. It also provided both trans-chlorocyclopropane diastereomers of callipeltoside A which allows the C-20 and C-21 configuration to be established as S and R, respectively. The convergent nature of the synthesis in which the largest piece, the macrolatone, require only 16 linear steps imparts utility to this strategy for the establishment of the structure-activity relationship. Initial biological testing demonstrates the irrelevance of the chloro substituent and the necessity of the sugar.

Stereoselective Synthesis of (+/-)-(cis-6-Methyltetrahydropyran-2-yl)acetic Acid

The title compound (1) has been synthesized in seven steps and in 42percent overall yield from the nucleophilic diene (2).The relative configuration of (1) has been confirmed by single-crystal X-ray study.

A Convenient Preparation of 6-Substituted-2-methoxy-5,6-dihydro-2H-pyrans via Cyclocondensation of Aldehydes with Danishefsky's Diene

Cyclocondensation of various aldehydes with Danishefsky's diene, followed by reduction of 2-substituted-2,3-dihydropyran-4-ones, and then by the Ferrier transformation of the resulting 2-substituted-2,3-dihydro-4H-pyran-4-ols, affords 6-substituted-2-meth

SYNTHESIS OF 2-ALKYL-2,3-DIHYDRO-γ-PYRONES FROM 1-METHOXY-1-BUTEN-3-YNE

A method for the preparation of 2-alkyl-2,3-dihydro-γ-pyrones from 1-methoxy-1-buten-3-yne 1 and aliphatic aldehydes is reported.